Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

pertuzumab-trastuzumab-hyaluronidase-zzxf

pertuzumab-trastuzumab-hyaluronidase-zzxf
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Phesgo INJECTION, SUBCUTANEOUS 80 mg-40 mg-2000 units/mL, 60 mg-60 mg-2000 units/mL      
Comments:

Phesgo is restricted to use by Oncology in the outpatient setting in patients who are intolerant to intravenous trastuzumab or pertuzumab. Insurance certification or PAP eligibility review are required prior to treatment.

 

Reviewed: August 2021

Last updated: Sep. 10, 2021






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved